 It is now in phase II trials and has been since 2002.In July 2010 in Europe, prolonged-release melatonin (Circadin, Neurim Pharmaceuticals) was approved for use for 13 weeks for insomnia patients over 55 years old.Additionally, Neurim Pharmaceuticals reported the results of a positive phase II trial of its investigational compound piromelatine (Neu-P11) in February 2013.